Evidence & Performance Blog

We had the pleasure to meet Doctor Pierre Le Sourd, former President of Bristol Myers Squibb France and most recently President of the Leem (The French Pharmaceutical Companies Association).

Mr Le Sourd brings us 30 years of pharmaceutical experience to help us understand current challenges and perspectives in this industry.

Read more

And the winner is … PAREXEL !

A couple of weeks ago we learned that Parexel has made an offer of $182 million to acquire ClinPhone, providing software to ease patient recruitment and manage clinical trial data.
Once Parexel made the offer back in June, Quintiles also got interested in the acquisition.

However Quintiles now steps back from the table and they will most likely develop in-house technology to reduce costs of trials.

It looks like Parexel can now complete the acquisition !

If you want to understand why the pharmaceutical industry is currently undergoing a transition, I am recommending you to read this interesting report from PricewaterhouseCoopers.

PWC clearly “indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.”

As I mentioned earlier, it is clear that the Pharma. must quickly find the way to improve its R&D productivity. For us, it is only by measuring the performance that the companies are able to set goals and drive for improvement. This has been demonstrated in others business as finance, and ultimately will prove itself in Drug or Medical Device Development.

Do not hesitate to share your impression with us! 

Pharma 2020 : The vision - which path will you take?
A report from PricewaterhouseCoopers